From small molecules to sequences: prepare for a new discovery landscape
Scientific Conference and User Group Meeting
Frankfurt, Germany
4-5th November, 2025
What is Certainty Discovery
Join us for the latest Certainty customer summit: Certainty Discovery. This two-day event showcases the combined expertise of Certara, Chemaxon, and their global community of customers, empowering scientists and research informaticians to achieve greater certainty in drug discovery.
Day 1 features a scientific conference with renowned industry speakers discussing the impact of new modalities on therapy discovery.
Day 2 focuses on practical solutions offered by our discovery software suite, including D360, Certara AI, Design Hub, Compound Registration and Marvin. Don’t miss this opportunity to advance your research!
Why join?

Prepare for New Modalities
Learn successful strategies for navigating the informatics challenges posed by sequence-based modalities.

Explore New Technologies
Discover our combined capabilities and future vision, including the application of deep learning to text search, optical structure recognition, property prediction model retraining, and more. Discuss how our experts can support you.

Network with Peers
Connect with fellow Certara and Chemaxon customers who share your passion for drug discovery.
Speakers
Adrian Stevens joined Chemaxon as Chief Product Officer in 2022. Adrian has spent approximately 15 years working in Life Sciences software companies, in product management roles for most of his time.
As a computational chemist at BioFocus PLC, over the course of nearly 10 years, he supported a wide range of areas in therapeutic research, from oncology, metabolic diseases, autoimmune and pain-based medicines. During this time, he specialized in designing small molecule drugs that targeted protein kinases and GPCR proteins, leading to a number of scientific publications and patents.
Adrian has a PhD in Computational Chemistry from the University of Portsmouth.
Richard Jones is currently SVP of Chemaxon an industry-leading cheminformatics company. Prior to joining Chemaxon Richard worked in a variety of different chemistry related companies. Richard helped found eChemicles as CEO, which develops technology that converts waste CO2 to chemicals using solar energy. He currently resides as a board member there. Before eChemicles, Richard worked for ThalesNano in a variety of positions from Head of Chemistry to CEO helping to develop the R&D 100 Award winning products as well as implementing their Lab of the Future strategy. Richard has also worked as CEO for InnoStudio, a scientific incubator company, helping to develop nanoformulation technology that reduces pesticide application by over 20 times.
At the start of his career Richard was at Biofocus Discovery (now Charles River) and worked on the synthesis of several Kinase and GPCR inhibitor based compound libraries. Richard has a Masters in Chemistry from the University of Bristol and a PhD in Chemistry from the University of Szeged. He has over 20 scientific papers, books, and patents to his name.
Dr. Filip Miljković holds an MPharm degree from the University of Niš, Serbia, and a PhD degree in Computational Life Sciences from the University of Bonn, Germany. In 2020, he joined AstraZeneca, Sweden where he currently works as an Associate Principal AI Scientist in Medicinal Chemistry within the Department of Early Cardiovascular, Renal and Metabolism. He also maintains a close connection to academia, remaining affiliated with his former academic group at the University of Bonn, Germany, and holds a visiting researcher position at Uppsala University, Sweden. His research interests include chemoinformatics and computational methodologies for medicinal chemistry and chemical biology, with a focus on machine learning and data science approaches for molecular property prediction.
Globally recognised as a thought-leader in cheminformatics and computational drug discovery, Nathan is the inventor of the first multi-objective de novo molecular design system, published in 2004, and has published over 50 papers and four books on the field. Nathan is the 2017 recipient of the Corwin Hansch Award – an award given by the Hansch-Fujita Foundation for significant contributions to the field of computer-aided drug design. He is also an elected Fellow of the Royal Societies of Chemistry, Biology, and The Arts.
Nathan has worked in senior leadership positions at BenevolentAI and Healx, building and leading large interdisciplinary teams. Prior to this, Nathan was Head of In Silico Medicinal Chemistry at The Institute of Cancer Research in London where he founded and led the In Silico Medicinal Chemistry team for over ten years. In this capacity, he delivered significant scientific impact on drugs in active clinical trials, and was responsible for the development of new algorithms for drug discovery. He was also a Presidential Research Fellow at the Novartis Institutes for BioMedical Research and a Marie Curie Research Fellow at Avantium.
Xin Zhang is the Senior Director of Cheminformatics and Platform Integration at Cellarity, where he leads the development of the cheminformatics roadmap and builds platforms to leverage small-molecule data to support lead optimization research programs.
Previously, he played a key role in Scientific Computing at X-Chem, focusing on developing software tools for DNA-Encoded Library (DEL) design and advancing AI/ML strategies for DEL screening hit identification. Before X-Chem, he served as the IT Business Partner at Celgene, where he developed the R&D IT roadmap and spearheaded multiple informatics initiatives to support Celgene’s Cambridge R&D site.
Dr. Miklos Feher is Senior Director of Computational Chemistry at X-Chem Inc., where he focuses on the discovery of novel drugs for challenging biological targets and the advancement of computational tools to support this mission. With over 30 years of experience leading computational chemistry teams in the pharmaceutical and biotech industries, Dr. Feher has made significant contributions to drug discovery, including 15 patents, several compounds in clinical development, 105 peer-reviewed publications, and two textbooks.
John is currently Expert Scientist and Group Leader in Medicinal Chemistry at Roche pRED in Basel, Switzerland. He has led chemistry teams on multiple projects in several disease areas and played a leading role in the introduction of a next generation informatics environment for medicinal chemists facilitating improved data visualisation and analysis, and prediction-led compound design. He also co-organises international medicinal chemistry conferences as a member of the Fine Chemicals Group committee of the SCI. Prior to moving to Roche in 2014 John worked at AstraZeneca in the UK for 19 years as a medicinal chemist mainly in the anti-inflammatory disease area and then as Global Programme Manager for Predictive Chemistry with responsibility for the strategic development of a suite of chemistry design and analysis tools.
John gained a PhD at Cambridge University in organic synthesis and then undertook post-doctoral research at Columbia University. He is an author of 32 scientific articles and an inventor on 25 patent applications.
With 16+years of experience in the Roche Pharma R&D informatics, Shijun has developed a deep expertise in building end-to-end biological workflows with FAIR principles, establishing information and data models for the emerging areas, and facilitating the data integration, querying and visualization to accelerate the drug discovery. In the last five years, she managed and developed the D360 platform as the key portfolio dashboard to advance the data-driven decision-making in Roche Pharma Early Research and Development (pRED) organization, spanning cross-therapeutic areas and modalities (i.e. small molecule, oligo, biologics, and gene therapy).
Sameh Eid is a trained pharmacist who earned his Ph.D. in computational drug design from the University of Basel. He then joined the BioMed X Innovation Center in Heidelberg, where he developed novel computational methods to optimize protein kinase selectivity. Since 2017, Sameh has been part of the Healthcare Digital, Data & IT team at Merck, focusing on research data systems and the integration of biologics and ADC with processing and analysis tools, including Certara D360.
Agenda

More speakers and detailed agenda is coming soon
Venue
Design Offices Frankfurt Wiesenhüttenplatz